Last reviewed · How we verify
Niacin/ Laropiprant
Niacin reduces triglycerides and LDL cholesterol while raising HDL cholesterol; laropiprant is a prostaglandin D2 receptor antagonist that reduces niacin-induced flushing.
Niacin reduces triglycerides and LDL cholesterol while raising HDL cholesterol; laropiprant is a prostaglandin D2 receptor antagonist that reduces niacin-induced flushing. Used for Dyslipidemia (elevated triglycerides and/or low HDL cholesterol) in patients at risk for cardiovascular disease.
At a glance
| Generic name | Niacin/ Laropiprant |
|---|---|
| Also known as | Tredaptive, EU/1/08/459/001 |
| Sponsor | Ludwig-Maximilians - University of Munich |
| Drug class | Lipid-modifying agent; prostaglandin D2 receptor antagonist |
| Target | DGAT2 (niacin); DP1 prostaglandin receptor (laropiprant) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Niacin (vitamin B3) works as a lipid-modifying agent by inhibiting hepatic diacylglycerol acyltransferase-2 (DGAT2) and affecting lipoprotein metabolism. Laropiprant blocks the DP1 prostaglandin receptor, which mediates the vasodilatory flushing response that commonly limits niacin tolerability. The combination allows higher niacin doses to be used with improved tolerability.
Approved indications
- Dyslipidemia (elevated triglycerides and/or low HDL cholesterol) in patients at risk for cardiovascular disease
Common side effects
- Flushing
- Hyperglycemia
- Hyperuricemia
- Gastrointestinal upset
Key clinical trials
- Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133) (PHASE3)
- Lipid Efficacy of the Extended Release Niacin/Laropiprant Combination in Patients With Cardiovascular Disease (PHASE4)
- Effect of Tredaptive on Serum Lipoproteins and Inflammatory Markers (PHASE4)
- A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED) (PHASE1)
- ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART (PHASE4)
- Effect of Nicotinic Acid on Cardiovascular Risks Indices in Polycystic Ovary Syndrome (PHASE4)
- MK-0524B Lipid Study (MK-0524B-063) (PHASE3)
- Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Niacin/ Laropiprant CI brief — competitive landscape report
- Niacin/ Laropiprant updates RSS · CI watch RSS
- Ludwig-Maximilians - University of Munich portfolio CI